ArriVent BioPharma Total Long Term Liabilities 2022-2025 | AVBP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ArriVent BioPharma total long term liabilities from 2022 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

ArriVent BioPharma Total Long Term Liabilities 2022-2025 | AVBP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ArriVent BioPharma total long term liabilities from 2022 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$220.6B
Amgen (AMGN)	$158.8B
Gilead Sciences (GILD)	$136.4B
Vertex Pharmaceuticals (VRTX)	$120.4B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$78.4B
CSL (CSLLY)	$76.6B
Regeneron Pharmaceuticals (REGN)	$61.3B
Alnylam Pharmaceuticals (ALNY)	$41.1B
Argenex SE (ARGX)	$34.2B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$19.7B
Insmed (INSM)	$18.6B
Illumina (ILMN)	$15.7B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$13B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Roivant Sciences (ROIV)	$7.7B
Repligen (RGEN)	$7.3B